Exelixis is transforming the challenges of drug development into opportunities to create innovative therapies with significant clinical and commercial potential.

Corporate Profile

Exelixis, Inc., from the Greek word for “evolution,” is a biopharmaceutical company committed to developing and commercializing small molecule therapies with the potential to improve the treatment of cancer.

Over the past decade, we have established a broad development platform, laying the foundation for our continued efforts to bring new therapies for cancer to patients in need. The history of our lead compounMore >>

EXEL (Common Stock)
ExchangeNASDAQ (US Dollar)
Change (%) Stock is Down 0.26 (2.33%)
Data as of 10/27/16 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore >>
10/20/16Exelixis to Release Third Quarter 2016 Financial Results on Thursday, November 3, 2016Printer Friendly Version
10/10/16Exelixis Announces Positive Results from Phase 2 CABOSUN Trial of Cabozantinib Versus Sunitinib in Previously Untreated Advanced Renal Cell Carcinoma Presented at ESMO 2016Printer Friendly Version
10/07/16Exelixis Announces Genentech Presentation of Preliminary Phase 1b Results for the Combination of Cobimetinib, Vemurafenib and Atezolizumab at ESMO 2016 CongressPrinter Friendly Version
10/07/16Exelixis Announces Phase 1 Trial Results for Cabozantinib in Combination with Nivolumab in Advanced Genitourinary TumorsPrinter Friendly Version
Upcoming EventsMore >>
Q3 2016 Exelixis Inc. Financial Results Conference Call
Thursday, November 3, 2016 5:00 p.m. ET
Add to Calendar Add Q3 2016 Exelixis Inc. Financial Results Conference Call   to Calendar  Help
remind me days before the event

Enter your e-mail address 
Featured Report
Download Documentation2015 Annual Report (pdf)
Download Documentation2014 Annual Report (pdf)

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.